The evolution of thalidomide and its IMiD derivatives as anticancer agents

JB Bartlett, K Dredge, AG Dalgleish - Nature Reviews Cancer, 2004 - nature.com
Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for
causing serious congenital birth defects. Remarkably, thalidomide was subsequently …

[HTML][HTML] Chronic immune activation and inflammation as the cause of malignancy

KJ O'Byrne, AG Dalgleish - British journal of cancer, 2001 - nature.com
Several chronic infections known to be associated with malignancy have established
oncogenic properties. However the existence of chronic inflammatory conditions that do not …

Origins of HIV and the evolution of resistance to AIDS

JL Heeney, AG Dalgleish, RA Weiss - Science, 2006 - science.org
The cross-species transmission of lentiviruses from African primates to humans has selected
viral adaptations which have subsequently facilitated human-to-human transmission. HIV …

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

AG Dalgleish, PCL Beverley, PR Clapham… - Nature, 1984 - nature.com
Acquired immune deficiency syndrome (AIDS) is characterized by opportunistic infections
and by 'opportunistic neoplasms'(for example, Kaposi's sarcoma) 1. Persistent generalized …

The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

PJ Maddon, AG Dalgleish, JS McDougal, PR Clapham… - Cell, 1986 - cell.com
The isolation of clones encoding the human surface protein T4, and the expression of the T4
gene in new cellular environments, have enabled us to examine the role of this protein in the …

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

C Galustian, B Meyer, MC Labarthe, K Dredge… - Cancer Immunology …, 2009 - Springer
Abstract Lenalidomide (Revlimid®; CC-5013) and pomalidomide (CC-4047) are IMiDs®
proprietary drugs having immunomodulatory properties that have both shown activity in …

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

K Dredge, R Horsfall, SP Robinson, LH Zhang… - Microvascular …, 2005 - Elsevier
The thalidomide analogue and immunomodulatory drug (IMiD®) lenalidomide (CC-5013,
REVLIMID™) is emerging as a useful treatment for a number of cancers and has recently …

Epitopes of the CD4 antigen and HIV infection

QJ Sattentau, AG Dalgleish, RA Weiss, PCL Beverley - Science, 1986 - science.org
The CD4 (or T4) surface antigen of human T lymphocytes is an important part of the receptor
for the human immunodeficiency virus (HIV). After binding to the receptor, the HIV may enter …

Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer

AG Dalgleish, KJ O'Byrne - 2002 - Elsevier
Infection with the human immunodeficiency virus (HIV) invariably leads to the development
of acquired immunodeficiency syndrome (AIDS) in most infected humans, yet does so rarely …

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type …

K Dredge, JB Marriott, SM Todryk… - The Journal of …, 2002 - journals.aai.org
Thalidomide and its novel T cell costimulatory analogs (immunomodulatory drugs) are
currently being assessed in the treatment of patients with advanced cancer. However …